Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Unresectable Stage III or Stage IV Melanoma
NCT05428007Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Feb 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in melanoma, sponsored by NYU Langone Health. Started Feb 2023; status: recruiting.
02
Drugs
sarilumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05428007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428007.